Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

Not Applicable

Terminated

Conditions: Inflammatory Breast Carcinoma
Breast Neoplasm

Interventions: Procedure: Photoacoustic Imaging

First Posted Date: 2012-12-24

Last Posted Date: 2021-06-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT01755130

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Phase 1

Completed

Conditions: Leukemia

Interventions: Other: Heavy Water (2H2O)
Drug: PCI-32765

First Posted Date: 2012-12-19

Last Posted Date: 2020-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01752426

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1

Terminated

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Minimal Residual Disease
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

Interventions: Drug: Dasatinib
Drug: Imatinib Mesylate
Drug: Nilotinib
Drug: Ruxolitinib

First Posted Date: 2012-12-18

Last Posted Date: 2025-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01751425

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Other: Best Systemic Therapy (BST)
Other: Best Systemic Therapy (BST) + Surgery or Radiation Therapy
Behavioral: Questionnaires
Other: Phone Call/Email

First Posted Date: 2012-12-18

Last Posted Date: 2023-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 180

Registration Number: NCT01751438

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
Vancouver Prostate Center, Vancouver, British Columbia, Canada

and more 1 locations

Ipilimumab and Lenalidomide in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Ipilimumab
Drug: Lenalidomide

First Posted Date: 2012-12-17

Last Posted Date: 2019-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 101

Registration Number: NCT01750983

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Phase 2

Recruiting

Conditions: Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Other: Laboratory Biomarker Analysis
Drug: Ponatinib Hydrochloride
Other: Quality-of-Life Assessment

First Posted Date: 2012-12-11

Last Posted Date: 2025-03-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01746836

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Armodafinil
Other: Placebo
Drug: Minocycline
Behavioral: Questionnaires

First Posted Date: 2012-12-10

Last Posted Date: 2018-06-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01746043

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dasatinib and Crizotinib in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Crizotinib
Drug: Dasatinib

First Posted Date: 2012-12-07

Last Posted Date: 2023-06-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01744652

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

Phase 1

Withdrawn

Conditions: Brain Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-04

Last Posted Date: 2018-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01740570

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions: Biological: Aldesleukin
Biological: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: NGFR-transduced Autologous T Lymphocytes
Other: Quality-of-Life Assessment

First Posted Date: 2012-12-04

Last Posted Date: 2024-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01740557

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy